May 8, 2013
According to AbbVie, the Food and Drug Administration (FDA) has given its new hepatitis C drug regimen a breakthrough therapy designation, which will speed up its potential approval in the United States. The FDA's designation stems from clinical trial results, which have shown a high response rate to the combination therapy in which patients receive 1224 weeks of treatment with nearly one year of post-treatment follow-up.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Gene Therapy in HIV Cure Research|
|Making HIV -- and Bias -- 'Part of the Party' to Strengthen Our Response to the Epidemic|
|One Doc's Advice for Caring for Elderly Patients With HIV|
|Bias Is Everywhere: Uncovering HIV Prejudice to Improve Service Delivery|
|Who Tends to Gain Weight With HIV Treatment?|